First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake Journal Article


Authors: Pandit-Taskar, N.; O'Donoghue, J. A.; Ruan, S.; Lyashchenko, S. K.; Carrasquillo, J. A.; Heller, G.; Martinez, D. F.; Cheal, S. M.; Lewis, J. S.; Fleisher, M.; Keppler, J. S.; Reiter, R. E.; Wu, A. M.; Weber, W. A.; Scher, H. I.; Larson, S. M.; Morris, M. J.
Article Title: First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake
Abstract: We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-IAB2M), an anti-prostate-specific membrane antigen minibody, in patients with metastatic prostate cancer. Methods: Patients received 185 MBq (5 mCi) of 89Zr-IAB2M and Df-IAB2M at total mass doses of 10 (n = 6), 20 (n = 6), and 50 mg (n = 6). Wholebody and serum clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated, and the effect of mass escalation was analyzed. Results: Eighteen patients were injected and scanned without side effects. Whole-body clearance was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L). The radiation absorbed dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an effective dose of 0.41mSv/MBq (1.5 rem/mCi). Both skeletal and nodal lesions were detected with 89Zr-IAB2M, most visualized by 48-h imaging. Conclusion: 89Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic prostate cancer. Imaging with 10 mg of minibody mass provides optimal biodistribution, and imaging at 48 h after injection provides good lesion visualization. Assessment of lesion targeting is being studied in detail in an expansion cohort. COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Keywords: dosimetry; psma; minibody; 89zr- iab2m; prostate cancer imaging
Journal Title: Journal of Nuclear Medicine
Volume: 57
Issue: 12
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2016-12-01
Start Page: 1858
End Page: 1864
Language: English
DOI: 10.2967/jnumed.116.176206
PROVIDER: scopus
PUBMED: 27516450
PMCID: PMC5450345
DOI/URL:
Notes: Article -- Export Date: 3 January 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Glenn Heller
    369 Heller
  2. Michael Morris
    395 Morris
  3. Shutian Ruan
    50 Ruan
  4. Jason S Lewis
    353 Lewis
  5. Steven M Larson
    906 Larson
  6. Sarah Marie Cheal
    37 Cheal
  7. Martin Fleisher
    295 Fleisher
  8. Howard Scher
    1041 Scher
  9. Wolfgang Andreas Weber
    170 Weber